FOI release

Freedom of Information request on the adverse reactions reported from the Channel Islands, Jersey and Guernsey (FOI 22/446)

Published 31 May 2022

FOI 22/446

2nd March 2022

Dear

Thank you for your emails received on the 3rd and 10th February, where you asked for information on the reported adverse drug reactions (including the number of fatalities and reported reactions) from the Channel Islands, Jersey and Guernsey.

I can confirm that the MHRA does hold some of the information that you have requested. However, we have also determined that the information is exempt under Section 12 of the Freedom of Information Act and we cannot process your request any further.

Section 12 of the Act allows public authorities to refuse requests where the cost of dealing with them would exceed the appropriate limit, which for central government is set at £600. This represents the estimated cost of one person spending 24 working hours in determining whether the department holds the information, locating, retrieving and extracting the information. You have made three substantially similar requests within 60 working days of an original request (FOI 22-036) which have been aggregated into one for the purposes of calculating a cost limit, meaning that section 12 applies.

We appreciate your interest in Yellow Cards reports received from your local area however, providing this information to you on a frequent basis has resulted in your request falling under section 12 of the Freedom of Information Act. We would be interested to understand the purpose of your request (i.e. how you are using this information and why regular updates are necessary) in order to help meet your requirements in future.

If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review would be carried out by a senior member of the Agency who was not involved with the original decision.

If you have a query about the information provided, please reply to this email.

Yours sincerely,

FOI Team,

Vigilance and Risk Management of Medicines Division